TCG CROSSOVER MANAGEMENT LLC
Q1 2025 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001839948
· CRD 311718
· SEC-registered investment adviser
$733.1M Reported Value Total
TCG CROSSOVER MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $1,799,709,770, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $3.8B gross asset value
Other: $3.8B
Source: Form ADV filed 2026-05-29
Reported value
$733.1M
Quarter over quarter
-27.2%
Holdings
37
Top-10 concentration
55.3%
Key People
Form ADV owners & control persons
Chen Ming Yu
MANAGING PARTNER
Craig David Skaling
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2025 13F record
Q1 2025 13F filing summary
| Period of report | March 31, 2025 |
|---|---|
| Filed | May 14, 2025 |
| Form | 13F-HR |
| Reported value | $733.1M |
| Positions | 37 |
| Change in reported value | -28.4% |
| New positions | 0 |
| Exited positions | 1 |
| Position turnover | 2.6% |
| Top-10 concentration | 55.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
54 | $4.2B |
|
Q1 2026 13F
Filed May 15, 2026
|
49 | $3.5B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
43 | $3.0B |
|
Q3 2025 13F
Filed Nov 17, 2025
|
40 | $2.0B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
37 | $875.5M |
|
Q1 2025 13F
Filed May 14, 2025
|
37 | $733.1M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
38 | $1.0B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
36 | $1.2B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
32 | $959.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
33 | $1.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $901.7M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
26 | $679.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
22 | $609.8M |
|
Q1 2023 13F
Filed May 15, 2023
|
22 | $513.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
21 | $566.6M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
21 | $333.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
22 | $235.4M |
|
Q1 2022 13F
Filed May 16, 2022
|
20 | $249.1M |
|
Q4 2021 13F
Filed Feb 18, 2022
|
15 | $213.6M |
Top 20 holdings · Q1 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CGON CG ONCOLOGY INC | $89.9M | 12.26% |
| 2 | COGT COGENT BIOSCIENCES INC | $41.7M | 5.69% |
| 3 | CNTA CENTESSA PHARMACEUTICALS PLC | $41.6M | 5.67% |
| 4 | MLYS MINERALYS THERAPEUTICS INC | $39.2M | 5.35% |
| 5 | OCUL OCULAR THERAPEUTIX INC | $39.0M | 5.32% |
| 6 | ABVX ABIVAX SA AMERICAN DEPOSITARY SHARES | $37.9M | 5.16% |
| 7 | SVRA SAVARA INC | $34.2M | 4.67% |
| 8 | DYN DYNE THERAPEUTICS INC | $27.7M | 3.78% |
| 9 | DNTH DIANTHUS THERAPEUTICS INC | $27.2M | 3.72% |
| 10 | TYRA TYRA BIOSCIENCES INC | $27.0M | 3.68% |
| 11 | XNCR XENCOR INC | $26.1M | 3.56% |
| 12 | IRON DISC MEDICINE INC | $23.1M | 3.15% |
| 13 | TRML TOURMALINE BIO INC | $22.5M | 3.07% |
| 14 | CDTX CIDARA THERAPEUTICS INC | $21.7M | 2.96% |
| 15 | AMLX AMYLYX PHARMACEUTICALS INC | $21.0M | 2.87% |
| 16 | SLNO SOLENO THERAPEUTICS INC | $19.6M | 2.68% |
| 17 | EYPT EYEPOINT PHARMACEUTICALS INC | $19.4M | 2.64% |
| 18 | GPCR STRUCTURE THERAPEUTICS INC | $18.4M | 2.51% |
| 19 | UPB UPSTREAM BIO INC | $17.1M | 2.34% |
| 20 | RAPT RAPT Therapeutics, Inc. | $16.0M | 2.18% |
Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.